利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.048 秒)

    Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    2.
    发明授权
    Compositions and methods for the identification, assessment, prevention and therapy of human cancers 失效
    用于鉴定，评估，预防和治疗人类癌症的组合物和方法

    公开(公告)号：US08080368B2

    公开(公告)日：2011-12-20

    申请号：US12956500

    申请日：2010-11-30

    申请人： Edwin Clark ,  Tallessyn Grenfell-Lee ,  Karen Lu ,  Lynn Hartmann ,  Jeffrey L. Brown ,  Robert C. Bast, Jr. ,  Gordon B. Mills

    发明人： Edwin Clark ,  Tallessyn Grenfell-Lee ,  Karen Lu ,  Lynn Hartmann ,  Jeffrey L. Brown ,  Robert C. Bast, Jr. ,  Gordon B. Mills

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： G01N33/6893 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2500/00 ,  G01N2800/52

    摘要： The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

    摘要翻译： 本发明涉及可用于确定肿瘤是否对治疗剂敏感或抗性的标志物的鉴定。 本发明还涉及治疗靶标的鉴定。 本发明特征在于许多“灵敏度标记物”。这些标记物在大多数或所有细胞系中表达，对于用药剂治疗敏感并且在细胞中不表达（或以相当低的水平表达） 耐药性。 本发明还具有许多“抗性标记”。这些标记物在大多数或所有细胞系中表达，其对于用药剂治疗有抗性并且在细胞中不表达（或以相当低的水平表达） 对该药物的治疗敏感。 本发明还具有可以预测可能响应或不响应于药剂的患者的标记物组。

    NOEY2 gene compositions and methods of use
    10.
    发明授权
    NOEY2 gene compositions and methods of use 失效
    NOEY2基因组成及使用方法

    公开(公告)号：US07183401B1

    公开(公告)日：2007-02-27

    申请号：US10166325

    申请日：1998-03-20

    申请人： Yinhua Yu ,  Fengji Xu ,  Robert C. Bast, Jr.

    发明人： Yinhua Yu ,  Fengji Xu ,  Robert C. Bast, Jr.

    IPC分类号： C07H21/04 ,  C12N15/00 ,  C12N5/00

    CPC分类号： C07K14/4703 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  C12N2799/021

    摘要： Disclosed are compositions and methods comprising a novel tumor suppressor gene, designated NOEY2, that is expressed in normal ovarian and breast surface epithelial cells but consistently absent or down-regulated in ovarian and breast cancer cells. Disclosed are polynucleotide compositions comprising a NOEY2 gene from mammalian sources, and polypeptides encoded by these nucleic acid sequences. Also disclosed are methods for preparing NOEY2 polypeptides, transformed host cells, and antibodies reactive with NOEY2 polypeptides. In certain embodiments, the invention describes methods for diagnosing and treating cancers, as well as methods for identifying NOEY2-related polynucleotide and polypeptide compositions.

    摘要翻译： 公开了包括在正常卵巢和乳腺表面上皮细胞中表达但在卵巢和乳腺癌细胞中一贯缺失或下调的称为NOEY2的新型肿瘤抑制基因的组合物和方法。 公开了包含来自哺乳动物来源的NOEY2基因的多核苷酸组合物和由这些核酸序列编码的多肽。 还公开了制备NOEY2多肽，转化的宿主细胞和与NOEY2多肽反应的抗体的方法。 在某些实施方案中，本发明描述了用于诊断和治疗癌症的方法，以及用于鉴定NOEY2相关多核苷酸和多肽组合物的方法。